Table 4.
Antimicrobial activities of relevant HsrA inhibitors against C. jejuni and several representative members of normal human microbiota.
| Inhibitor or Drug | MIC (MBC), mg/L | ||||||
|---|---|---|---|---|---|---|---|
|
C. jejuni ATCC 33560 |
E. coli ATCC 25922 |
K. pneumoniae
ATCC 700603 |
E. faecalis ATCC 29212 |
S. aureus ATCC 29213 |
S. epidermidis
ATCC 12228 |
S. agalactiae
ATCC 12386 |
|
| I | 32 (32) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | 32 (64) |
| IV | 64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) |
| V | 0.25 (0.5) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) |
| VIII | 16 (32) | >64 (>64) | >64 (>64) | 64 (64) | 16 (32) | 4 (4) | 16 (32) |
| XI | >64 (>64) | >64 (>64) | >64 (>64) | 64 (64) | 16 (32) | 16 (64) | 8 (8) |
| XII | 64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) | >64 (>64) |
| LVX | <0.12 (<0.12) | N.D. | 0.5 (0.5) | N.D. | N.D. | N.D. | N.D. |
| AMP | N.D. | 4 (4) | N.D. | 4 (4) | 2 (4) | 4 (4) | 0.25 (0.5) |
LVX, levofloxacin. AMP, ampicillin. MIC, minimal inhibitory concentration. MBC, minimal bactericidal concentration.